Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22436585 | 0.84 | SMN1; SMN2 (0.42) | SLC5A2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL22436542 | 0.83 | SMN1; SMN2 (0.45) | CYP4F2CYP4A11SLC5A2NPC1RAB9A | |
| SCHEMBL9518703 | 0.83 | CYP4F2 (0.41) | CYP4F2CYP4A11SLC5A2SPHK2SPHK1 | |
| SCHEMBL334828 | 0.79 | MEN1 (0.40) | CYP4F2CYP4A11SLC5A2NPC1RAB9A | |
| SCHEMBL334680 | 0.77 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL7255668 | 0.73 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL9281772 | 0.73 | TDP1 (0.41) | CYP4F2CYP4A11SLC5A2SMN1; SMN2GAA | |
| SCHEMBL22436578 | 0.72 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL9946117 | 0.71 | KMT2A (0.44) | NPC1RAB9ASMN1; SMN2MEN1CYP2C19 | |
| SCHEMBL22436579 | 0.71 | HTR2C (0.43) | NPC1RAB9ASMN1; SMN2MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-111491939-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3710457-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3710457-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111491939-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024531-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP4F2 3818/4885CYP4A11 2998/4885SLC5A2 4415/4885 |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | CYP4F2 3818/4885CYP4A11 2998/4885SLC5A2 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.